Results 41 to 50 of about 10,960 (146)

Outbreak of aztreonam–avibactam-resistant NDM-5-producing Escherichia coli isolates in a hospital of Paris

open access: yesMicrobiology Spectrum
The emergence of aztreonam–avibactam resistance among NDM-producing Escherichia coli represents a major therapeutic and infection control concern. Four cases of aztreonam–avibactam-resistant (AZAR) NDM-producing E.
Véronique Faraut Derouin   +16 more
doaj   +1 more source

Comparison of the

open access: yesJournal of Global Antimicrobial Resistance
Objectives: To provide a descriptive analysis of the in vitro antimicrobial susceptibility testing results for all 39,661 Pseudomonas aeruginosa isolates collected by the ATLAS global surveillance programme data from 2020 to 2024 with a focus on ...
Mark A. Estabrook   +3 more
doaj   +1 more source

The Klebsiella pneumoniae carbapenemase (KPC) β-Lactamase Has Evolved in Response to Ceftazidime Avibactam

open access: yesAntibiotics, 2023
Klebsiella pneumoniae carbapenemase KPC is an important resistance gene that has disseminated globally in response to carbapenem use. It is now being implicated as a resistance determinant in Ceftazidime Avibactam (CAZ-AVI) resistance. Given that CAZ-AVI
Sona Garsevanyan, Miriam Barlow
doaj   +1 more source

ARC in Critical Ill OLT Recipients: True Prevalence, Risk Factors, and Impact on Early Aggressive PK/PD Target Non‐Attainment of CI Beta‐Lactam Therapy for Posttransplant Gram‐Negative Infections

open access: yesTransplant Infectious Disease, Volume 28, Issue 5, September/October 2026.
Augmented renal clearance (ARC) represents a quite prevalent condition among critical orthotopic liver transplant recipients (23.2%). ARC is associated with different demographics and clinical features and significantly affects the attainment of aggressive beta‐lactams pharmacokinetic/pharmacodynamic targets despite the administration of standard ...
Milo Gatti   +6 more
wiley   +1 more source

Successful Rapid Desensitization to Ceftazidime/Avibactam in a Patient With Cystic Fibrosis and Multidrug‐Resistant Pseudomonas aeruginosa Pneumonia: A Case Report

open access: yesClinical Case Reports, Volume 14, Issue 8, August 2026.
ABSTRACT Ceftazidime/avibactam (CAZ‐AVI) is an important therapeutic option for multidrug‐resistant (MDR) Pseudomonas aeruginosa infections; however, hypersensitivity reactions may preclude its use and create significant therapeutic challenges. We report a 21‐year‐old woman with cystic fibrosis and recurrent MDR P.
Zuoren Zhou   +6 more
wiley   +1 more source

Comparative effectiveness of ceftolozane/tazobactam relative to ceftazidime/avibactam for the treatment of adult, hospitalized patients with pneumonia due to multidrug-resistant Pseudomonas aeruginosa in U.S. Veterans Health Administration facilities

open access: yesAntimicrobial Agents and Chemotherapy
Ceftolozane/tazobactam (C/T) and ceftazidime/avibactam (C/A) are frequently used for the treatment of multidrug-resistant Pseudomonas aeruginosa (MDR-PSA) pneumonia. However, comparative “real-world” effectiveness data are limited.
Nicholas S. Britt   +4 more
doaj   +1 more source

Combination of Oral Doxycycline and Rifampin for Pan‐Drug Resistant Klebsiella pneumoniae Infection: A Case Report

open access: yesClinical Case Reports, Volume 14, Issue 8, August 2026.
ABSTRACT Pan‐drug resistant Klebsiella pneumoniae is a major therapeutic challenge, particularly when standard last‐line agents are unavailable or contraindicated. We report a 45‐year‐old man with multifocal osteomyelitis and persistent purulent wound discharge despite broad‐spectrum antibiotics, repeated debridement, and two sequential amputations ...
Ali Akbar Heydari   +2 more
wiley   +1 more source

Antimicrobial activity of ceftazidime-avibactam against KPC-2-producing Enterobacterales: a cross-combination and dose-escalation titration study with relebactam and vaborbactam

open access: yesMicrobiology Spectrum
With the introduction of ceftazidime-avibactam worldwide, the antimicrobial activity of new β-lactam/β-lactamase inhibitors (BL/BLIs) needs to be investigated.
Min Seo Kang   +13 more
doaj   +1 more source

Interactions between Avibactam and Ceftazidime-Hydrolyzing Class D β-Lactamases

open access: yesBiomolecules, 2020
Class D β-lactamases exhibit very heterogeneous hydrolysis activity spectra against the various types of clinically useful β-lactams. Similarly, and according to the available data, their sensitivities to inactivation by avibactam can vary by a
Jean-Marie Frère   +6 more
doaj   +1 more source

Longitudinal Molecular Epidemiology and Genomic Surveillance of Carbapenem‐Resistant Klebsiella pneumoniae in the Gut of Healthy Individuals in China

open access: yesMedComm, Volume 7, Issue 8, August 2026.
Using 16,040 stool samples from healthy individuals across 30 Chinese provinces (2016–2024), we performed longitudinal genomic surveillance of carbapenem‑resistant Klebsiella pneumoniae (CRKP) colonizing the gut. We reveal rising community CRKP prevalence, especially in southern China, a shift from blaKPC‐2 to plasmid‑borne blaNDM‐5 on IncHI2/IncHI2A ...
Zelin Yan   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy